Universitair Medisch Centrum Groningen

This site supports a broad oncology research portfolio focused on neoplasms across many solid and blood cancers. Studies commonly aim to test new cancer therapies, refine treatment combinations, and improve outcomes for patients with advanced or difficult-to-treat disease.

• Non-Small Cell Lung Cancer and Small Cell Lung Cancer
• Breast Cancer, Ovarian Cancer, and other solid tumors
• Advanced Solid Tumors and Metastatic Disease

Research at the Groningen site often explores whether newer targeted and immune-based approaches can improve survival, disease control, and tolerability compared with current standard care.

A major area of work involves hematologic cancers, especially lymphoma, leukemia, and multiple myeloma. The trials are designed to evaluate more effective treatment strategies for relapsed or high-risk disease and to expand the role of advanced immunotherapies.

• Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, and Follicular Lymphoma
• Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, and Myelodysplastic Syndrome
• CAR T-cell therapy, bispecific antibodies, and other targeted treatments

These studies aim to improve response rates, extend remission, and find safer options for patients whose disease has returned or no longer responds well to prior therapy.

The site has strong activity in thoracic oncology, with many trials in lung cancer covering both early and advanced stages. Research here focuses on better systemic treatment, personalized approaches, and ways to guide care using imaging or molecular markers.

• Non-Small Cell Lung Cancer, including advanced and resectable forms
• ROS1-positive, ALK-positive, and other molecularly defined tumors
• Small Cell Lung Cancer and Hodgkin Lymphoma with PET-guided strategies

Several studies at Universitair Medisch Centrum Groningen aim to match treatment more closely to tumor biology and to improve long-term outcomes while limiting unnecessary toxicity.

Another important theme is immune system diseases, including chronic inflammatory and autoimmune disorders. Trials in this area are testing new ways to reduce symptoms, control disease activity, and improve quality of life for people living with long-term immune-related conditions.

• Crohn's disease and Ulcerative colitis
• Systemic lupus erythematosus and lupus nephritis
• Psoriasis, hidradenitis suppurativa, and other immune-mediated skin disorders

The research often compares new therapies with existing care to determine whether symptoms, inflammation, and organ damage can be better controlled over time.

The trial portfolio also includes a substantial nephrology and transplantation focus. These studies examine kidney protection, transplant outcomes, and treatment options for chronic and progressive renal disorders.

• Chronic Kidney Disease and kidney failure
• Kidney transplant rejection and highly sensitized transplant recipients
• IgA Nephropathy, proteinuria, and related glomerular diseases

The goal is to preserve kidney function, improve transplant success, and identify therapies that may slow disease progression in patients with limited treatment options.

The site conducts studies in cardiovascular disease and related cardiorenal conditions, reflecting interest in both prevention and treatment. Research includes heart failure, coronary disease, rhythm disorders, and strategies to reduce complications after major cardiac procedures.

• Heart Failure and heart failure with preserved or reduced ejection fraction
• Atrial Fibrillation, Coronary Artery Disease, and myocardial infarction
• Cardiac surgery, valve disease, and transcatheter aortic valve implantation

These trials are aimed at improving symptom control, preventing hospitalizations, and lowering the risk of major cardiovascular events through better treatment choices.

A wide range of digestive system diseases is represented, including inflammatory, malignant, and liver-related conditions. The research seeks better therapies for cancer, symptom relief, and improved management of chronic gastrointestinal disease.

• Colorectal Cancer, rectal cancer, and gastric cancer
• Hepatocellular carcinoma and biliary tract cancer
• Primary sclerosing cholangitis, PSC-related pruritus, and alcoholic liver cirrhosis

The studies range from testing new anticancer strategies to evaluating treatments that may ease symptoms and support organ function in chronic liver and bowel disease.

The research landscape also includes nervous system diseases, mental disorders, and selected rare conditions. Trials address both neurological decline and mental health, with an emphasis on better symptom management and functional improvement.

• Parkinson's disease, multiple sclerosis, and Alzheimer's disease
• Depression and treatment-resistant depression
• Rare genetic and metabolic disorders such as glycogen storage disease and phenylketonuria

These studies are designed to improve daily functioning, slow progression, and explore new treatment options where existing care remains limited.